Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Incorporation of novel renoprotective treatments into routine clinical practice is recommended in international guidelines for appropriate patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). However, physicians may not be aware of the optimal management strategies to reduce renal decline and cardiovascular complications. The goal of this activity was to better prepare clinicians to implement best practice, guideline recommended clinical management of CKD in patients with T2D.
A multidisciplinary panel of experts delivered a 30-minute online video discussion with synchronized slides. Educational effect was assessed using a repeated-pair design with pre-/post-assessment. Two multiple choice questions assessed knowledge, one question assessed competence, and one question assessed confidence rated on a Likert-type scale. A paired samples t-test was conducted on overall average number of correct responses and for confidence rating, a McNemar’s test was conducted at the question level.
Of 1555 learners who participated in the activity between 1/3/2025 and 1/30/2025, 88 learners who answered all the assessment questions were included in the analysis. Overall, 33% of diabetologists/endocrinologists (n=43, P<.001) and 42% of nephrologists (n=45, P<.001) improved their knowledge and competence regarding the management of CKD in patients with T2D. Significant areas of improvement included knowledge of the clinical profile (benefits and safety) of nonsteroidal mineralocorticoid receptor antagonists (45% relative change for nephrologists, P<0.1), and knowledge regarding the latest guideline recommendations for patients with CKD and T2D (22% relative change for diabetologists/endocrinologists, P<0.5). Post education, 42% of diabetologists/endocrinologists and 27% of nephrologists had greater confidence in their ability to use novel therapies for their patients with T2D and CKD. For those that increased confidence, the average confidence shift was 38% for nephrologists (P<.001) and 60% for diabetologists/endocrinologists (P<.05), respectively. Furthermore, there was a 171% increase in the number of diabetologists/endocrinologists and 65% increase in the number of nephrologists who became very confident to use novel therapies for their patients with T2D and CKD after the education. When asked about their intent to change practice, 42% of diabetologists/endocrinologists and 32% of nephrologists reported that they will more frequently prescribe novel drugs (SGLT2i, GLP-1 RA, ns-MRA) for their patients with T2D and CKD because of the education.
Participation in an online video expert discussion improved understanding among diabetologists/endocrinologists and nephrologists of the best practice, guideline recommended clinical management of CKD in patients with T2D.
